Novo Nordisk A/SNVONYSE
Loading
Book Value/Share Growth Recovery in ProgressRecovering
Percentile Rank79
3Y CAGR-73.1%
5Y CAGR+4.7%
Year-over-Year Change
Year-over-year book value per share growth
3Y CAGR
-73.1%/yr
vs +1092.5%/yr prior
5Y CAGR
+4.7%/yr
Recent deceleration
Acceleration
-1165.6pp
Decelerating
Percentile
P79
Within normal range
vs 5Y Ago
1.3x
Solid growth
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 14.16% |
| Q3 2025 | 1.11% |
| Q2 2025 | 21.11% |
| Q1 2025 | -3.14% |
| Q4 2024 | 19.05% |
| Q3 2024 | 645.97% |
| Q2 2024 | -83.64% |
| Q1 2024 | -7.07% |
| Q4 2023 | 709.31% |
| Q3 2023 | -0.10% |
| Q2 2023 | 14.02% |
| Q1 2023 | -86.02% |
| Q4 2022 | 729.14% |
| Q3 2022 | -3.15% |
| Q2 2022 | 5.48% |
| Q1 2022 | -85.87% |
| Q4 2021 | 588.13% |
| Q3 2021 | -1.06% |
| Q2 2021 | 13.53% |
| Q1 2021 | -10.73% |
| Q4 2020 | 11.26% |
| Q3 2020 | 4.14% |
| Q2 2020 | 13.62% |
| Q1 2020 | -7.04% |
| Q4 2019 | -83.61% |
| Q3 2019 | 0.23% |
| Q2 2019 | 12.66% |
| Q1 2019 | -7.71% |
| Q4 2018 | 8.98% |
| Q3 2018 | -2.73% |
| Q2 2018 | 11.47% |
| Q1 2018 | -10.03% |
| Q4 2017 | 5.95% |
| Q3 2017 | -3.64% |
| Q2 2017 | 22.37% |
| Q1 2017 | -10.38% |
| Q4 2016 | 10.14% |
| Q3 2016 | -2.58% |
| Q2 2016 | 14.58% |
| Q1 2016 | -19.87% |